Antimalarial Activity of the Anticancer Histone Deacetylase Inhibitor SB939
نویسندگان
چکیده
منابع مشابه
Potent antimalarial activity of histone deacetylase inhibitor analogues.
The malaria parasite Plasmodium falciparum has at least five putative histone deacetylase (HDAC) enzymes, which have been proposed as new antimalarial drug targets and may play roles in regulating gene transcription, like the better-known and more intensively studied human HDACs (hHDACs). Fourteen new compounds derived from l-cysteine or 2-aminosuberic acid were designed to inhibit P. falciparu...
متن کاملAntimalarial activity of phenylthiazolyl-bearing hydroxamate-based histone deacetylase inhibitors.
The antimalarial activity and pharmacology of a series of phenylthiazolyl-bearing hydroxamate-based histone deacetylase inhibitors (HDACIs) was evaluated. In in vitro growth inhibition assays approximately 50 analogs were evaluated against four drug resistant strains of Plasmodium falciparum. The range of 50% inhibitory concentrations (IC(50)s) was 0.0005 to >1 microM. Five analogs exhibited IC...
متن کاملAnticancer activity of MS-275, a novel histone deacetylase inhibitor, against human endometrial cancer cells.
BACKGROUND Histone deacetylase inhibitors (HDACIs) can inhibit cell proliferation, induce cell cycle arrest and stimulate apoptosis of cancer cells. MATERIALS AND METHODS The effects of a novel HDACI, MS-275, on 4 endometrial cancer cell lines and normal human endometrial epithelial cells was investigated. Endometrial cancer cells were treated with various concentrations of MS-275 and its eff...
متن کاملNBM-HD-1: A Novel Histone Deacetylase Inhibitor with Anticancer Activity
HDAC inhibitors (HDACis) have been developed as promising anticancer agents in recent years. In this study, we synthesized and characterized a novel HDACi, termed NBM-HD-1. This agent was derived from the semisynthesis of propolin G, isolated from Taiwanese green propolis (TGP), and was shown to be a potent suppressor of tumor cell growth in human breast cancer cells (MCF-7 and MDA-MB-231) and ...
متن کاملHistone deacetylase inhibitors as novel anticancer therapeutics
Histone deacetylase inhibitors represent a promising new class of compounds for the treatment of cancer. Inhibitors of this kind currently under clinical evaluation mainly target the classical (Rpd3/Hda1) family of histone deacetylases. Of particular note, the U.S. Food and Drug Administration recently approved the first histone deacetylase inhibitor (Zolinza: Merck and Co., Whitehouse Station,...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Antimicrobial Agents and Chemotherapy
سال: 2012
ISSN: 0066-4804,1098-6596
DOI: 10.1128/aac.00030-12